Article

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma

2023-01-19

Abstract excerpt

Ovarian high-grade serous carcinoma (HGSC) is the most common and lethal subtype of ovarian cancer with limited therapeutic options. In recent years, PARP inhibitors have demonstrated significant clinical benefits, especially in patients with BRCA1/2 mutations. However, acquired drug resistance and relapse is a major challenge. Therapies disrupting the spliceosome alter cancer transcriptomes and have shown potenti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ac14c354-8dc1-5561-9feb-e99c443832ea
DOI: 10.1101/2023.01.18.524417

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinomaDOI 10.1101/2023.01.18.524417Read

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.Semantic proximity Read

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.Semantic proximity Read

A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiencySemantic proximity Read

Indisulam exerts anticancer effects on human cervical carcinoma cells via induction of aberrant splicing, cycle arrest, and apoptosisSemantic proximity Read

Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma modelsSemantic proximity Read

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degradersSemantic proximity Read

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitorsSemantic proximity Read

Targeting RRM2 Enhances PARP Inhibitor Efficacy in Ovarian Cancer CellsSemantic proximity Read

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell CarcinomaSemantic proximity Read

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.Semantic proximity Read

YAP/TAZ interacts with RBM39 to confer resistance against indisulamSemantic proximity Read

Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15.Semantic proximity Read